

A Brief Overview of Nevirapine

Mr. Digvijay B. Patil¹, Mr. Raturaj P. Gadhave², Dr. Naga R. Potnuri³, Mrs. Waghmode P.A⁴

^{1,2}Mandesh Institute of Pharmaceutical Science and Research centre, Mhasawad, Satara.

³Principal, Mandesh Institute of Pharmaceutical Science and Research centre, Mhasawad, Satara.

⁴Assistant Prof., Mandesh Institute of Pharmaceutical Science and Research centre, Mhasawad, Satara.

Abstract—Nevirapine is a highly specific inhibitor of HIV-1 reverse transcriptase (RT), which is an important therapeutic target in the treatment of HIV infection. It was the first non-nucleoside RT inhibitor (NNRTI) approved for use in HIV-infected individuals, including children. Nevirapine inhibits the replication of several HIV-1 strains and clinical isolates in cultured human T cells, but has no activity against other retroviral RTs (including HIV-2 RT) or endogenous human DNA polymerases. Nevirapine monotherapy rapidly selects for advanced drug resistance caused by a single amino acid substitution in the HIV RT gene. The pattern of resistance mutations selected by nevirapine overlaps with other NNRTIs, but differs from that of nucleoside analog RT inhibitors and protease inhibitors. The pharmacokinetics of nevirapine is characterized by rapid and almost complete oral absorption, apparently uniform distribution in all body organs and tissues, and a long elimination half-life. Nevirapine is metabolized by cytochrome P450 isoenzymes and induces their activity. Caution should be exercised when nevirapine is co-administered with other drugs metabolized by this system, including HIV protease inhibitors.

Index Terms—Nevirapine (NVP), HIV protease inhibitors, ADR, Mechanism of action, HPLC approach.

I. INTRODUCTION

Nevirapine (NVP) is one of the oldest antiretrovirals (ARV) drugs for the treatment of HIV infection and is still widely used. More than one million patient years of worldwide experience have provided a significant amount of data to better understand this non-nucleoside antiretroviral inhibitor (NNRTI) [1,2].

Nevirapine is one of the most widely used ARV drugs in Africa and Asia, giving it an important role in the global fight against HIV infection. As the first NNRTI approved by the US Food and Drug Administration (FDA), NVP has a well-understood and widely described safety profile [3]. Although it may have

some drawbacks, recent data suggest that it may be an acceptable regimen in certain populations. Health Care and Personnel Management Guide [4].

Nevirapine (NVP), sold under the brand name Viramune among others, is a drug used to treat and prevent HIV/AIDS, particularly HIV-1. It is usually recommended to be used in combination with other antiretroviral drugs. It can be used to prevent mother-to-child transmission during childbirth, but is not recommended after exposure to others. It is taken orally. Common side effects include rash, headache, nausea, fatigue and liver problems. Liver problems and rash may be serious and should be monitored during the first months of treatment. It appears to be safe to use during pregnancy. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and blocks the activity of the reverse transcriptase enzyme. Nevirapine was approved for medical use in the United States in 1996. It is on the World Health Organization's List of Essential Medicines [5,6].

II. ADVERSE EFFECT

The most common adverse effect of nevirapine is the development of mild or moderate rash (13%). Severe or life-threatening skin reactions have been observed in 1.5% of patients, including Stevens–Johnson syndrome, toxic epidermal necrolysis and hypersensitivity. Nevirapine may cause severe or life-threatening liver toxicity, usually emerging in the first six weeks of treatment [7].

In 2000, the U.S. Food and Drug Administration issued a black box warning on nevirapine, warning that it could cause life-threatening liver toxicity and skin reactions. Unacceptably high risk of serious liver symptoms in certain patient groups (women with CD4 count >250 and men >400) has led the U.S [8].

DHHS to recommend the restriction of nevirapine use to those at lower risk, unless the benefit to the patient clearly outweighs the risk. Although in the 2NN study which found these CD4 limits, the effect was seen only in patients recruited from Thailand. The nevirapine drug substance is a white to off-white crystalline powder. Nevirapine is highly lipophilic. It is only slightly soluble in water (0.1 mg/ml), forming a clear colorless solution, and is relatively insoluble in non-polar media [9, 10]. The nevirapine used in the formation of the tablets is anhydrous with a molecular weight of 266.3 g/mol. It is a low molecular weight compound that is lipophilic (partition coefficient = 83) and has a weak base ($pK_a = 2.8$). At pH values below the pK_a , nevirapine is very soluble in an aqueous buffer [11, 12]. At higher pH values, the water solubility of nevirapine decreases asymptotically to about 0.1 mg/ml. Nevirapine is a weak base because of the two pyridine nitrogens. The ionization constants measured are $pK_{a1} = 2.8$; $pK_{a2} = -0.4$. The first and second ionization constants were determined by spectrophotometry (UV) and by NMR, respectively. Nevirapine exhibits solubility in chloroform; sparingly soluble in methanol [13].

III. MECHANISM OF ACTION

Nevirapine belongs to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of antiretroviral drugs. Both nucleoside and non-nucleoside RTIs inhibit the same target, reverse transcriptase, an important viral enzyme that transcribes viral RNA into DNA. Unlike nucleoside RTIs, which bind to the polymerase active site, NNRTIs bind to a hydrophobic pocket in the p66 subdomain about 10 angstroms from the active site (known as the NNRTI pocket). Therefore, this NNRTI-binding pocket inhibits reverse transcription in a manner different from RTIs. Nevirapine is not effective against HIV-2 because the reverse transcriptase pocket of HIV-2 has a different structure that confers intrinsic resistance to the NNRTI class. Resistance to nevirapine develops rapidly if viral replication is not completely inhibited [14,15]. The most commonly observed mutations after nevirapine treatment are Y181C and K103N, which are also seen with other NNRTIs. Because all NNRTIs bind in the same pocket, viral strains resistant to nevirapine are usually also resistant to the other NNRTIs, efavirenz and delavirdine. However, second-

generation NNRTIs such as rilpivirine and etravirine are effective in the treatment of HIV strains resistant to nevirapine and other first-generation drugs of the same class [16,17,18].

IV. CHEMISTRY

Nevirapine has two chemical names: de 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3']-[1,4]-diazepin-6-one and 5, 11-dihydro-6H-11-cyclopropyl-4-methyldipyrido-[3,2-b:2',3'-e1]-[1,4]-diazepin-6-one [19, 20,21].

The molecular formula is $C_{18}H_{14}N_4O$. Nevirapine medication is a white or off-white crystalline powder. Nevirapine is highly lipophilic. It is slightly soluble (0.1 mg/ml) in water to form a clear colorless solution and is relatively insoluble in non-polar media. The nevirapine used in the composition of the tablet is anhydrous and has a molecular weight of 266.3. Nevirapine has no possible geometric isomers, and since it has no asymmetric center, optical isomers cannot exist. Nevirapine is a weak base due to the two pyridine nitrogens [22].




Fig - Chemical structure of Nevirapine

The measured ionization constants are $pK_{a1} = 2.8$; $pK_{a2} = -0.4$. The first and second ionization constants were determined spectrophotometrically (W) and NMR, respectively. Nevirapine is a very stable compound. At pH 3 and pH 11, half-lives were determined to be approximately 1200 and 700 days, respectively [23].

In the stability studies of the bulk drug, no degradation of the drug was observed for five years. No special storage requirements are necessary. The shelf life of Nevirapine 200 mg tablets in plastic bottles is 30 months and the shelf life of 200 mg tablets in blister packs is 24 months if stored at 15-30°C [24].

The commercial 200 mg tablet is identical to the formulation used in clinical trials. Other formulations

of nevirapine prepared for clinical trials include other tablets, oral suspension, intravenous injection, and oral solution prepared at the clinical site [25].

V. PHARMACODYNAMICS PROPERTIES

Dipyridodiazepinonevirapine is a non-nucleoside inhibitor (NNRTI) of HIV-1 reverse transcriptase (RT). Nevirapine binds directly to the HIV-1 RT, slowing the rate of viral DNA synthesis before insertion into the host cell genome, thus preventing viral replication in acutely infected cells [26].

Nevirapine inhibited the replication of several HIV-1 strains and clinical isolates in human T cells cultured in vitro with a 50% inhibitory concentration (IC₅₀) of approximately 40 nmol/L (10.6 µg/L) as determined by cytopathic inhibition of a virus. effect It did not inhibit other retroviral RTs, including HIV-2 RT or human endogenous DNA polymerases. Nevirapine had very low cytotoxicity in uninfected human cells [27].

Complete suppression of viral replication was achieved when nevirapine was added to cultured cells within 24 hours of HIV-1 infection, but activity was limited when the drug was added later. This is consistent with inhibition of the early stages of the retroviral life cycle and activity against acute HIV infection. Short-term administration of nevirapine to chimpanzees, initiated immediately before HIV-1 vaccination, was sufficient to protect animals from productive or chronic infection, although evidence of proviral integration was observed [27].

The antiretroviral activity of nevirapine was synergistic with zidovudine, lamivudine, or stavudine against wild-type HIV-1 in vitro. Nevirapine was effective alone or synergistically with lamivudine or stavudine against zidovudine-resistant virus. Nevirapine reduced the accumulation of HIV-1 reverse transcriptase in cell-free virions, which appears to be required for efficient virion infectivity. This activity affects the control of HIV transmission of cell-free virions in physiological fluids such as semen, cervical secretions, blood plasma and breast milk.

NNRTIs, including nevirapine, are associated with the rapid development of drug-resistant viral mutants when used as monotherapy in HIV-infected patients or after limited transmission of HIV-1 in the presence of an inhibitor in vitro [29, 30].

The most common HIV-1 RT mutation selected by nevirapine both in vitro and in vivo is a tyrosine to cysteine change at residue 181 (Y181C). This variant is more than 100-fold less sensitive to nevirapine than the wild-type virus and confers cross-resistance to other NNRTIs. Acquisition of the Y181C mutation renders zidovudine-resistant HIV variants susceptible to NRTIs. Nevirapine-resistant variants selected for zidovudine resistance contained a valine to alanine change at residue 106 (V106A) instead of Y181C. This virus variant is resistant to both nevirapine and zidovudine [31, 32].

VI. PHARMACOKINETIC PROPERTIES

Nevirapine pharmacokinetics in adults are characterized by rapid and nearly complete oral absorption, an apparently even distribution throughout all organs and tissues in the body, and a long elimination half-life (t_{1/2}) of approximately 40 hours. The recommended adult dosage of nevirapine 200mg twice daily produced an average steady-state plasma concentration of 5.5 mg/L in healthy volunteers. An oral suspension of nevirapine has shown bioavailability similar to that of the tablet in doses up to 200mg. Nevirapine suspension was rapidly absorbed after administration of single oral doses of 7.5 to 120 mg/m² in 9 HIV-infected children. Maximum plasma concentrations (C_{max}) were achieved within 4 hours and reached 0.3 to 2.9 mg/L (1 to 10 µmol/L), up to 273 times higher than the nevirapine IC₅₀ for wild-type virus [33].

Nevirapine increases its metabolism by inducing cytochrome P450 (CYP) isoenzymes (mainly CYP3A). This results in an approximately twofold increase in the systemic clearance of nevirapine in both adults and children after repeated administration for 2-4 weeks. Young children (and over 6 years of age) appear to eliminate nevirapine more quickly than older children, suggesting that the dose should be adjusted according to age. Population kinetic analyzes indicate that nevirapine 7 mg/kg or 150 mg/m² twice daily in children 8 years of age and 4 mg/kg or 120 mg/m² in children 8 years and older would produce nevirapine concentrations equivalent to 200 mg in adults [34].

Radioactivity studies in healthy male volunteers showed that approximately 81.3% of a total oral dose of nevirapine was excreted in the urine and 10.1% in

the face, mainly as hydroxylase glucuronide metabolites [35].

Nevirapine was found to cross the placenta efficiently after a single oral 200mg dose to the mother at the onset of labour. This resulted in cord blood nevirapine concentrations well above the target concentration of 100 µg/L (10 times the in vitro IC₅₀ for HIV-1) thought to be necessary for prevention of perinatal HIV transmission. The median t_{1/2} of nevirapine in the mothers was 61.3 to 65.7 hours. In infants, median t_{1/2} was 45.4 to 72.1 hours for elimination of the maternal nevirapine dose, and 36.8 to 46.5 hours for elimination of a single 2 mg/kg neonatal dose [36, 37].

VII. CLINICAL EFFICACY

A. Prevention of Perinatal HIV Transmission-

The favorable pharmacokinetic profile of nevirapine prompted its evaluation as a single-dose regimen for the prevention of late intrauterine and perinatal transmission of HIV. HIVNET 012, a phase IIB/III randomized, open-label study, evaluated the efficacy of nevirapine or ultrashort-course zidovudine in preventing HIV transmission from infected pregnant women (n = 626) to their newborns. Nevirapine treatment consisted of a single 200 mg oral tablet taken by the mother at the onset of labor and a single dose of nevirapine suspension (2 mg/kg) administered to the neonate within 72 hours after birth (median 24–30 hours). Zidovudine therapy was started with an oral dose of 600 mg at the onset of labor, followed by 300 mg every 3 hours during labor [38].

A neonate received oral zidovudine syrup (4 mg/kg) twice daily for 7 days after birth. At 6-8 and 14-16 weeks postpartum, HIV infection was significantly higher in the zidovudine group than in the nevirapine group (25.1 vs. 13.1%). HIV-free survival 14-16 years. week was equally higher in the nevirapine group than in the zidovudine group (85.6 vs. 72.4%). Thus, the risk of infant perinatal HIV infection or death in the first 4 months was reduced by 47% with nevirapine therapy in this predominantly (98.8%) breastfed population [39, 40].

B. Treatment of pediatric HIV infection-

Although antiviral efficacy of nevirapine has been demonstrated in randomized controlled trials in adult patients, studies of its therapeutic use in children are more limited. One randomized, open-label study with

nevirapine included pediatric patients (ACTG 245). Antiretroviral-treated patients with advanced disease (age 6 months to 20 years; n = 432) were randomized to triple therapy with nevirapine, zidovudine, and didanosine or dual therapy with either nevirapine and didanosine or zidovudine and didanosine (no dose manipulation). An interim analysis of 136 patients in patients showed that the triple therapy group achieved significantly greater reductions in mean plasma HIV RNA levels over 48 weeks than either of the dual therapy groups. Triple therapy also resulted in a sustained reduction in CSF viral load in patients with HIV-related encephalopathy. Initiation of triple therapy with nevirapine, zidovudine, and didanosine before 4 months of age in asymptomatic or mildly symptomatic perinatally HIV-infected infants significantly reduced viral load in a phase I/II open-label study [41].

Plasma HIV RNA levels decreased by 1.5 log₁₀ copies/mL in 5 of 6 children within 2 to 4 weeks of starting therapy and remained below baseline during 6 months of therapy. Another phase I/II trial showed the efficacy of triple therapy with nevirapine, zidovudine, and lamivudine in reducing viral load ≥ 2 log₁₀ copies/mL, which was sustained for 12 weeks in 12 of 15 children [42, 43].

C. Dosage and administration

To prevent perinatal HIV infection, HIV-infected pregnant women naïve to antiretroviral therapy may receive a single oral dose of 200 mg of nevirapine during labor. Subsequently, the HIV-infected neonate should receive a single dose of 2 mg/kg nevirapine oral suspension within 72 hours of delivery. Nevirapine is available as an oral suspension for children. The recommended dose for children aged 2 months to 8 years is 4 mg/kg once a day for 2 weeks, followed by 7 mg/kg twice a day [49].

D. Metabolism and elimination

Nevirapine increases its metabolism by inducing cytochrome P450 (CYP) isoenzymes (mainly CYP3A), which results in an approximately twofold increase in nevirapine systemic clearance during 2-4 weeks of repeated therapy. CYP3A autoinduction also results in a reduction in elimination half-life (t_{1/2}) from approximately 40 hours after a single dose to <30 hours at steady state in adult patients. The ACTG 180 study showed that, as in adults, repeated dosing of

nevirapine (120-240 mg/m²/day) in HIV-infected children (n = 21) resulted in a 1.5- to 2-fold increase in nevirapine clearance (CL). compared to a single dose [50].

The mean CL for a single dose of nevirapine was 0.9 L/m²/h (36.8 ml/kg/h) and the terminal half-life was 30.6 hours. Children younger than 6 years had a higher CL than older children (7-14 years; CL/F = 42.6 vs 29.5 ml/kg/h), suggesting that the dose should be adjusted according to age. Radiolabeling studies in healthy male adults showed that approximately 81.3% of a total oral dose of nevirapine was excreted in urine and 10.1% in feces, mainly as hydroxylated glucuronide metabolites (primarily 2-, 3-, and 12-hydroxynevirapine glucuronides); only 3.3% of the total dose was excreted unchanged in the urine [51, 52].

VIII. CLINICAL APPLICATIONS

A. Treatment of HIV-1 Infection

Nevirapine has demonstrated efficacy as part of combination antiretroviral therapy (cART) in treatment-naïve and experienced adults and children, achieving durable virologic suppression and immune restoration when used with other agents such as NRTIs. Clinical trials established that nevirapine-containing regimens can yield comparable outcomes to protease inhibitor (PI)-based regimens in ART-naïve patients, particularly in those with baseline CD4 counts above critical thresholds.

B. Prevention of Mother-to-Child Transmission

One of the landmark uses of nevirapine, especially in resource-limited settings, has been single-dose administration to mothers during labor and neonates postpartum to reduce vertical transmission. Early randomized trials demonstrated a significant reduction in perinatal HIV transmission compared with short courses of zidovudine. However, concerns about emergent resistance following single-dose exposure underscore the need for optimized strategies and combination regimens in prevention of mother-to-child transmission (PMTCT) protocols.

IX. SPECIAL POPULATIONS

Nevirapine has also been studied in paediatric populations and pregnant women, where its pharmacokinetics may differ due to physiological

changes. In pregnancy, altered elimination and placental transfer necessitate close evaluation of dosing and safety.

X. FUTURE PERSPECTIVES

Despite the advent of newer NNRTIs with improved safety and higher resistance barriers (e.g., rilpivirine, doravirine) and integrase strand transfer inhibitors (INSTIs), nevirapine retains relevance in certain settings due to cost and availability. Continued research into optimized combination strategies, especially in resource-limited regions, and pharmacogenomics to predict adverse risk could refine its clinical utility.

XI. CONCLUSION

Nevirapine is the first representative of a new class of antiretroviral compounds, non-nucleoside reverse transcriptase inhibitors, approved for use in HW-1 - infected individuals. Although clinical endpoint data were not completed, analysis of surrogate marker data indicates that nevirapine therapy in combination with nucleosides is associated with sustained antiviral and CD4 cell counts. Nevirapine is synergistic, and can be used safely with nucleoside analogs. Resistance to nevirapine is rapid and common when is administered intravenously. When used in combination with one or more nucleosides at the recommended dose, the development of clinically relevant resistance is reduced or delayed. Nevirapine is a stable and bioavailable substance that penetrates most tissues, including the central nervous system. It has favorable pharmacokinetics, allowing to be administered twice daily, except for the predictable and usually mild to moderate rash, nevirapine is safe and very well tolerated with few other side effects.

REFERENCES

- [1] Mohanraj, P., D. Kumar Sarkar, T. Choudhury, and K. Gauthaman, "A simple and rapid RP-HPLC method for the estimation of nevirapine in bulk and pharmaceutical dosage forms," *World Journal of Pharmaceutical Sciences*, vol. 5, no. S2, pp. 1081–1086, 2008. [Online]. Available: <http://www.e>

- [2] Yoon, H. Y., Y. A. Cho, J. Yee, and H. S. Gwak, "Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: A systematic review and meta-analysis," *Scientific Reports*, vol. 10, no. 1, Dec. 2020.
- [3] Namegabe, L. M., A. O. Mahano, and S. O. Sarr, "Development, validation and application of a spectrofluorimetric method for the quantification of nevirapine in pharmaceutical formulations tablets and suspensions," *American Journal of Analytical Chemistry*, vol. 13, no. 6, pp. 206–227, 2022.
- [4] V. Reddiah, C., P. Rama Devi, and K. Mukkanti, "Stability indicating HPLC method for impurities estimation of nevirapine in extended-release tablet dose," *Pharmacophore: An International Research Journal*, vol. 4, 2013. [Online]. Available: <http://www.pharmacophorejournal.com/>
- [5] Bhavyasri, K., G. Srihitha, D. Rambabu, and M. Sumakanth, "Development and validation of nevirapine—An anti-retroviral drug by UV-visible spectrophotometric method and its degradation study under various stress conditions," *Saudi Journal of Biomedical Research*, 2019. [Online]. Available: <http://scholarsmepub.com/sjbr/>
- [6] Sahoo, M., B. V. V. Ravi Kumar, N. K. Tripathy, and S. K. Patro, "Stability indicating RP-HPLC method for determination of nevirapine in pure and tablet form," *Der Pharma Chemica*, vol. 5, 2013. [Online]. Available: www.derpharmachemica.com
- [7] Wollinger, W., B. Da Motta Lessa, A. B. Da Nobrega, R. R. Riente, R. S. C. Lopes, C. C. Lopes, et al., "Simultaneous determination of assay and related substances in nevirapine suspension by HPLC," *Chromatographia*, vol. 75, nos. 15–16, pp. 893–901, Aug. 2012.
- [8] Rezk, N. L., R. R. Tidwell, and A. D. M. Kashuba, "Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection," *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, vol. 791, nos. 1–2, pp. 137–147, Jul. 2003.
- [9] Pollard, R. B., P. Robinson, and K. Dransfield, "Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection," *Clinical Therapeutics*, vol. 20, no. 6, pp. 1071–1092, 1998.
- [10] Fan, B., and J. T. Stewart, "Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 28, 2002. [Online]. Available: www.elsevier.com/locate/jpba
- [11] Pillay, P., N. Ford, Z. Shubber, and R. A. Ferrand, "Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: A systematic review and meta-analysis," *PLoS One*, vol. 8, no. 7, Jul. 2013.
- [12] Chi, J., A. L. Jayewardene, J. A. Stone, and F. T. Aweeka, "An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 31, no. 5, pp. 953–959, Apr. 2003.
- [13] Pav, J. W., L. S. Rowland, and D. J. Korpalski, "HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 20, 1999.
- [14] Bollinger, R. C., "Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: An analysis of three randomised controlled trials," *The Lancet*, vol. 372, no. 9645, pp. 300–313, 2008. [Online]. Available: www.thelancet.com
- [15] Shubber, Z., A. Calmy, I. Andrieux-Meyer, M. Vitoria, F. Renaud-Théry, N. Shaffer, et al., "Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: A systematic review and meta-analysis," *AIDS*, vol. 27, pp. 1403–1412, 2013.
- [16] Mustafa, S., H. Raja, P. Zainab, W. Nazirah, W. Yusuf, N. B. Hassan, et al., "Development and validation of HPLC-UV method for simultaneous determination of nevirapine, 2-OH nevirapine and 3-OH nevirapine in human plasma," *International Journal of PharmTech Research*, vol. 6, 2014. [Online]. Available:

<https://www.researchgate.net/publication/265844235>

- [17] Yong, C. L., J. C. Gathe, G. Knecht, C. Orrell, J. Mallolas, D. Podzamczar, et al., “Pharmacokinetic analysis of nevirapine extended release 400 mg once daily versus nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection,” *HIV Clinical Trials*, vol. 18, nos. 5–6, pp. 189–195, Nov. 2017.
- [18] Committee for Medicinal Products for Human Use (CHMP), Annex I: Summary of Product Characteristics, pp. 1–44, 2005.
- [19] Fogel, J., D. R. Hoover, J. Sun, L. M. Mofenson, M. G. Fowler, A. W. Taylor, et al., “Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis,” *AIDS*, vol. 25, no. 7, pp. 911–917, Apr. 2011.
- [20] K. Bichala, P., R. Suthakaran, A. Lawal, N. Kumar, A. K. Gurjar, and R. Singh, “Method development and its validation for simultaneous estimation of nevirapine and lamivudine by RP-HPLC in combination tablet dosage form,” *International Journal of Pharmaceutical, Chemical and Biological Sciences*, vol. 10, no. 1, pp. 15–19, 2020. [Online]. Available: www.ijpcbs.com.